New combo aims to shorten CLL treatment
NCT ID NCT07671378
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests two oral drugs, zanubrutinib and sonrotoclax, in 24 people with untreated high-risk CLL/SLL. The goal is to see if a time-limited treatment guided by minimal residual disease (MRD) can achieve deep remission. Participants take the drugs for up to 27 cycles, with dosing adjusted based on response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib and sonrotoclax (oral drugs)
What this could lead to
If successful, this could offer a time-limited treatment option for high-risk CLL/SLL, potentially reducing the need for lifelong therapy.
What could go wrong
This is a small, early-phase trial (24 participants) with no control group. The combination may cause side effects or fail to achieve deep remission, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••